X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
y-90-dotatoc (201) 201
radiology, nuclear medicine & medical imaging (123) 123
humans (98) 98
neuroendocrine tumors (94) 94
oncology (71) 71
index medicus (70) 70
dosimetry (62) 62
radionuclide therapy (59) 59
receptor radionuclide therapy (59) 59
octreotide - analogs & derivatives (56) 56
toxicity (54) 54
survival (51) 51
radiolabeled somatostatin analog (50) 50
octreotide - therapeutic use (45) 45
male (44) 44
radiotherapy (40) 40
tumors (39) 39
radiopharmaceuticals - therapeutic use (38) 38
female (37) 37
middle aged (37) 37
neuroendocrine tumors - radiotherapy (37) 37
lu-177-dotatate (36) 36
phase-i (33) 33
nuclear medicine (31) 31
aged (29) 29
prrt (29) 29
octreotide (28) 28
medicine & public health (27) 27
peptide receptor radionuclide therapy (27) 27
adult (26) 26
cancer (26) 26
lu-177-octreotate (26) 26
peptides (25) 25
somatostatin - analogs & derivatives (25) 25
kidney (23) 23
neuroendocrine tumours (23) 23
imaging / radiology (22) 22
organometallic compounds - therapeutic use (21) 21
treatment outcome (21) 21
phase-ii (20) 20
somatostatin receptors (20) 20
cardiology (19) 19
orthopedics (19) 19
endocrinology & metabolism (18) 18
octreotate (18) 18
octreotide - adverse effects (18) 18
receptors, somatostatin - metabolism (18) 18
therapy (18) 18
biodistribution (17) 17
carcinoid-tumors (17) 17
radiopharmaceuticals (17) 17
renal toxicity (17) 17
somatostatin - therapeutic use (17) 17
diagnosis (16) 16
medicine, research & experimental (16) 16
radionuclide imaging (16) 16
radiotherapy dosage (16) 16
scintigraphy (16) 16
radioimmunotherapy (15) 15
radioisotopes - therapeutic use (15) 15
y-90 (15) 15
animals (14) 14
internal radiotherapy (14) 14
neuroendocrine tumors - diagnostic imaging (14) 14
neuroendocrine tumors - metabolism (14) 14
pharmacology & pharmacy (14) 14
renal uptake (14) 14
efficacy (13) 13
ga-68-dotatoc (13) 13
pet (13) 13
positron-emission-tomography (13) 13
somatostatin (13) 13
tyr octreotate (13) 13
aged, 80 and over (12) 12
expression (12) 12
management (12) 12
radiation therapy (12) 12
radiopharmaceuticals - adverse effects (12) 12
receptors, peptide - metabolism (12) 12
somatostatin analogs (12) 12
somatostatin receptor (12) 12
somatostatin receptor scintigraphy (12) 12
yttrium radioisotopes - therapeutic use (12) 12
gastroenteropancreatic tumors (11) 11
kidney - radiation effects (11) 11
localization (11) 11
lu-177-dota,tyr octreotate (11) 11
organometallic compounds - adverse effects (11) 11
y-dotatoc (11) 11
analog (10) 10
chemotherapy (10) 10
experience (10) 10
in-vivo (10) 10
kidneys (10) 10
liver metastases (10) 10
neuroendocrine tumors - pathology (10) 10
pharmacokinetics (10) 10
radiometry (10) 10
radiopeptide therapy (10) 10
somatostatin-analog (10) 10
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


EUROPEAN JOURNAL OF ENDOCRINOLOGY, ISSN 0804-4643, 01/2015, Volume 172, Issue 1
Peptide receptor radionuclide therapy (PRRT) is a promising new treatment modality for inoperable or metastasized gastroenteropancreatic neuroendocrine tumors... 
RADIOLABELED SOMATOSTATIN ANALOG | SURVIVAL | Y-90-DOTATOC | Y-90 | LU-177-OCTREOTATE | ENDOCRINOLOGY & METABOLISM | PHASE-II | SALVAGE THERAPY | LU-177-DOTATATE | TOXICITY | CONVENTIONAL THERAPY
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 11/2014, Volume 41, Issue 11, pp. 2106 - 2119
Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter such as Y-90/Lu-177-DOTATOC is a new therapeutic option in... 
Y-90-DOTATOC | DOTATOC | METASTASES | SOMATOSTATIN-ANALOG | TOXICITY | COMBINATION | ARTERIAL | Bi-213 | Targeted alpha therapy (TAT) | Ac-225 | MYELOID-LEUKEMIA | GA-68-DOTATOC | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, ISSN 0928-1258, 05/2017, Volume 41, Issue 3, pp. 237 - 238
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 12/2011, Volume 52, Issue 12, pp. 1864 - 1870
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent... 
Y-90-DOTATOC | SOMATOSTATIN ANALOGS | SCINTIGRAPHY | GUIDELINES | SST1-SST5 | PEPTIDE | Ga-68-DOTATOC PET/CT | Ga-68-DOTATATE PET/CT | RECEPTOR RADIONUCLIDE THERAPY | CONTRAST | NET | EXPRESSION | DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
CANCER, ISSN 0008-543X, 06/2008, Volume 112, Issue 11, pp. 2447 - 2455
BACKGROUND. The aim was to assess the relevant distribution of the novel PET tracer Ga-68-DOTATATE in neuroendocrine tumors (NETs) with combined positron... 
endocrine system | DIAGNOSIS | PEPTIDE RECEPTORS | GRADING SYSTEM | KI-67 | POSITRON-EMISSION-TOMOGRAPHY | PHARMACOKINETICS | ONCOLOGY | CARCINOID-TUMORS | PET/CT | Y-90-DOTATOC THERAPY | SOMATOSTATIN RECEPTOR SCINTIGRAPHY | positron emission tomography | EXPRESSION | neuroendocrine tumors
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 11/2013, Volume 54, Issue 11, pp. 1857 - 1861
Myelosuppression may be the dose-limiting toxicity in peptide receptor radionuclide therapy (PRRT). The aim of this study was to investigate the incidence,... 
SURVIVAL | Y-90-DOTATOC | PRRT | hematotoxicity | GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | TOXICITY | FLUOROURACIL | BONE-MARROW DOSIMETRY | RADIOLABELED SOMATOSTATIN ANALOG | STREPTOZOCIN | Lu-177-octreotate | NETs | LU-177-DOTATATE | PHASE-I | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 10/2008, Volume 35, Issue 10, pp. 1847 - 1856
Purpose Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumours with Y-90-DOTATOC and Lu-177-DOTATATE is promising. The kidney is the critical... 
Y-90-DOTATOC | renal toxicity | NEUROENDOCRINE TUMORS | radionuclide therapy | dosimetry | BIODISTRIBUTION | RADIOTHERAPY | MODEL | PHASE-I | NEPHROPATHY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Lu-177-DOTATATE
Journal Article
BRITISH JOURNAL OF CANCER, ISSN 0007-0920, 04/2013, Volume 108, Issue 7, pp. 1440 - 1448
Background: Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with metastatic neuroendocrine tumours (NETs), although which... 
RADIOLABELED SOMATOSTATIN ANALOG | Y-90-DOTATOC | Yttrium-PRRT | neuroendocrine tumours (NETs) | RECIST | EFFICACY | ONCOLOGY | response | survival | OCTREOTATE | CHROMOGRANIN-A | RENAL UPTAKE
Journal Article
PANCREAS, ISSN 0885-3177, 05/2014, Volume 43, Issue 4, pp. 518 - 525
Objective Peptide receptor radionuclide therapy with radiolabeled somatostatin analogs is a novel method of treatment in patients with metastatic... 
SURVIVAL | Y-90-DOTATOC | ANALOG | EFFICACY | peptide receptor radionuclide therapy | SCINTIGRAPHY | OCTREOTATE | ACTIVITY IN-111 PENTETREOTIDE | GEP TUMORS | GASTROENTEROPANCREATIC TUMORS | 177Lu-DOTATATE | QUALITY-OF-LIFE | GASTROENTEROLOGY & HEPATOLOGY | neuroendocrine tumors
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 01/2013, Volume 54, Issue 1, pp. 33 - 41
The organs at risk in radionuclide therapy with Lu-177-octreotate are the bone marrow and the kidneys. The primary aim of this study was to develop an... 
RENAL DOSIMETRY | Y-90-DOTATOC | LU-177-OCTREOTATE | dosimetry | TYR OCTREOTATE | TOXICITY | DISSEMINATED NEUROENDOCRINE TUMORS | bone marrow | PEPTIDE | RADIOLABELED SOMATOSTATIN ANALOG | kidney | individualized | RECEPTOR RADIONUCLIDE THERAPY | LU-177-DOTATATE | Lu-177-DOTA-octreotate | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 06/2013, Volume 54, Issue 6, pp. 855 - 860
Measured human dosimetry of the Ga-68-labeled synthetic somatostatin analog Ga-68-DOTATATE has not been reported in the peer-reviewed literature.... 
Y-90-DOTATOC | SURVIVAL | dosimetry | RADIATION-EXPOSURE | INTERNAL DOSE ASSESSMENT | Ga-68-DOTATATE | RECEPTOR RADIONUCLIDE THERAPY | OCTREOTATE | PET/CT EXAMINATIONS | TOXICITY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | neuroendocrine tumors
Journal Article
ACTA ONCOLOGICA, ISSN 0284-186X, 2018, Volume 57, Issue 4, pp. 516 - 521
Background: Fractionated therapy with Lu-177-DOTATATE has been reported to be an effective treatment for patients with metastasized neuroendocrine tumors. To... 
RADIOLABELED SOMATOSTATIN ANALOG | Y-90-DOTATOC | SURVIVAL | LU-177-OCTREOTATE | ONCOLOGY | RECEPTOR RADIONUCLIDE THERAPY | OCTREOTATE | TOXICITY | INDIVIDUALIZED DOSIMETRY
Journal Article
JOURNAL OF NUCLEAR MEDICINE, ISSN 0161-5505, 02/2015, Volume 56, Issue 2, pp. 177 - 182
Peptide receptor radionuclide therapy (PRRT) is a promising treatment for patients with neuroendocrine tumors, giving rise to improved survival. Dosimetric... 
Y-90-DOTATOC | RECIST | dosimetry | RECOVERY COEFFICIENT | BONE-MARROW | VOLUME | OCTREOTATE | CANCER | RADIOLABELED SOMATOSTATIN ANALOG | RENAL TOXICITY | dose-response | KIDNEY | INDIVIDUALIZED DOSIMETRY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | neuroendocrine tumors | Lu-177-DOTATATE
Journal Article
BIOMED RESEARCH INTERNATIONAL, ISSN 2314-6133, 2013
Kidney dosimetry in Lu-177 and Y-90 PRRT requires 3 to 6 whole-body/SPECT scans to extrapolate the peptide kinetics, and it is considered time and resource... 
Y-90-DOTATOC | MEDICINE, RESEARCH & EXPERIMENTAL | PROBABILITY | BIOTECHNOLOGY & APPLIED MICROBIOLOGY | OCTREOTATE | TOXICITY
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 03/2014, Volume 41, Issue 3, pp. 505 - 510
Purpose Renal radiation during peptide receptor radionuclide therapy (PRRT) may result in glomerular damage, a potential reduction of glomerular filtration... 
Y-90-DOTATOC | SURVIVAL | PRRT | Y-90 | EFFICACY | GASTROENTEROPANCREATIC NEUROENDOCRINE TUMORS | PHASE-II | TOXICITY | RADIOLABELED SOMATOSTATIN ANALOG | Lu-177-octreotate | LU-177-DOTATATE | RADIOTHERAPY | NET | Nephrotoxicity | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 16, pp. 4617 - 4624
Journal Article
NEURO-ONCOLOGY, ISSN 1522-8517, 11/2016, Volume 18, Issue 11, pp. 1538 - 1547
Background. The prognosis of patients with progressive meningioma after failure of surgery and radiotherapy is poor. Methods. We retrospectively evaluated the... 
meningioma | Y-90-DOTATOC | ANALOG | somatostatin receptors | NEUROENDOCRINE CANCERS | TUMORS | CLINICAL NEUROLOGY | PHASE-II TRIAL | RADIOPEPTIDE THERAPY | ONCOLOGY | GRADE | CENTRAL-NERVOUS-SYSTEM | RECURRENT MENINGIOMA | EXPRESSION | PET | radionuclide
Journal Article
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, ISSN 1619-7070, 08/2017, Volume 44, Issue 9, pp. 1480 - 1489
Purpose To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment... 
Y-90-DOTATOC | SURVIVAL | PRRT | Renal function | CANCERS | Neuroendocrine | OCTREOTATE | TOXICITY | RADIOLABELED SOMATOSTATIN ANALOG | RECEPTOR RADIONUCLIDE THERAPY | Dosimetry | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Lu-177-DOTATATE
Journal Article
MEDICAL PHYSICS, ISSN 0094-2405, 12/2018, Volume 45, Issue 12, pp. 5577 - 5585
Purpose Neuroendocrine tumors (NETs) are now routinely treated by radiopeptide targeted therapy using somatostatin receptor-binding peptides such as Y-90- and... 
Y-90-DOTATOC | PRRT | NEUROENDOCRINE TUMORS | MANAGEMENT | dosimetry | EFFICACY | analytical solving | BIODISTRIBUTION | TOXICITY | biokinetic model | NUCLEAR-MEDICINE | RECEPTOR RADIONUCLIDE THERAPY | RADIOTHERAPY | BODY | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.